High flow therapy (HFT) has been demonstrated to be a safe and effective noninvasive respiratory support technique for the treatment of pre-term infants in neonatal intensive care. Our objective was to develop a quantitative framework based on available evidence to estimate the economic impact of adopting an HFT respiratory support strategy, compared to current standard of care.
